425 related articles for article (PubMed ID: 26644288)
21. SATB2 is not a reliable diagnostic marker for distinguishing between oral osteosarcoma and fibro-osseous lesions of the jaws.
Grad-Akrish S; Rachmiel A; Ben-Izhak O
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 May; 131(5):572-581. PubMed ID: 33309262
[TBL] [Abstract][Full Text] [Related]
22. Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells.
Thway K; Robertson D; Jones RL; Selfe J; Shipley J; Fisher C; Isacke CM
Br J Cancer; 2016 Aug; 115(4):473-9. PubMed ID: 27434038
[TBL] [Abstract][Full Text] [Related]
23. P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions.
Shooshtarizadeh T; Rahimi M; Movahedinia S
Pathol Res Pract; 2016 Oct; 212(10):876-879. PubMed ID: 27473669
[TBL] [Abstract][Full Text] [Related]
24. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
Bellizzi AM
Histopathology; 2020 Jan; 76(2):251-264. PubMed ID: 31233624
[TBL] [Abstract][Full Text] [Related]
25. Metformin reduces SATB2-mediated osteosarcoma stem cell-like phenotype and tumor growth via inhibition of N-cadherin/NF-kB signaling.
Xu HY; Fang W; Huang ZW; Lu JC; Wang YQ; Tang QL; Song GH; Kang Y; Zhu XJ; Zou CY; Yang HL; Shen JN; Wang J
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4516-4528. PubMed ID: 29131265
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical detection of bone morphogenetic proteins in bone and soft-tissue sarcomas.
Yoshikawa H; Rettig WJ; Lane JM; Takaoka K; Alderman E; Rup B; Rosen V; Healey JH; Huvos AG; Garin-Chesa P
Cancer; 1994 Aug; 74(3):842-7. PubMed ID: 8039112
[TBL] [Abstract][Full Text] [Related]
27. Value of SATB2 immunostaining in the distinction between small intestinal and colorectal adenocarcinomas.
Kim CJ; Baruch-Oren T; Lin F; Fan XS; Yang XJ; Wang HL
J Clin Pathol; 2016 Dec; 69(12):1046-1050. PubMed ID: 27169755
[TBL] [Abstract][Full Text] [Related]
28. Nuclear p63 expression in osteoblastic tumors.
Kallen ME; Sanders ME; Gonzalez AL; Black JO; Keedy VL; Hande KR; Homlar KC; Halpern JL; Holt GE; Schwartz HS; Coffin CM; Cates JM
Tumour Biol; 2012 Oct; 33(5):1639-44. PubMed ID: 22623071
[TBL] [Abstract][Full Text] [Related]
29. Malignant fibrous histiocytoma and fibrosarcoma of bone: a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approaches.
Romeo S; Bovée JV; Kroon HM; Tirabosco R; Natali C; Zanatta L; Sciot R; Mertens F; Athanasou N; Alberghini M; Szuhai K; Hogendoorn PC; Dei Tos AP
Virchows Arch; 2012 Nov; 461(5):561-70. PubMed ID: 23001328
[TBL] [Abstract][Full Text] [Related]
30. [Histopathological diagnostic concordance in bone and soft tissue sarcomas between two comprehensive cancer centers from eastern and western Europe: a collaborative experience].
Somcutian O; Buiga R; Galatir M; Tudor Eniu D; Rachieru C; Coza D; Terrier P
Ann Pathol; 2015 Jan; 35(1):32-40. PubMed ID: 25541117
[TBL] [Abstract][Full Text] [Related]
31. A novel antisense long non-coding RNA SATB2-AS1 overexpresses in osteosarcoma and increases cell proliferation and growth.
Liu SH; Zhu JW; Xu HH; Zhang GQ; Wang Y; Liu YM; Liang JB; Wang YX; Wu Y; Guo QF
Mol Cell Biochem; 2017 Jun; 430(1-2):47-56. PubMed ID: 28190168
[TBL] [Abstract][Full Text] [Related]
32. FGF23 Expression Is a Promising Immunohistochemical Diagnostic Marker for Undifferentiated Pleomorphic Sarcoma of Bone (UPSb).
Al-Hassi HO; Ali NM; Cooke H; De Silva S; Brini AT; Babu P; Sumathi V; Morris MR; Niada S
Genes (Basel); 2024 Feb; 15(2):. PubMed ID: 38397231
[No Abstract] [Full Text] [Related]
33. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone.
Ud Din N; Umer M; Park YK
Int J Surg Pathol; 2020 Dec; 28(8):859-867. PubMed ID: 32429739
[No Abstract] [Full Text] [Related]
34. Anti-CD10 (56C6) expression in soft tissue sarcomas.
Deniz K; Çoban G; Okten T
Pathol Res Pract; 2012 May; 208(5):281-5. PubMed ID: 22464152
[TBL] [Abstract][Full Text] [Related]
35. Lymphatic dissemination of bone and soft tissue sarcomas: a lymphographic investigation.
Tallroth K
Acta Radiol Suppl; 1976; 349():1-84. PubMed ID: 206099
[TBL] [Abstract][Full Text] [Related]
36. SATB2 is expressed in Merkel cell carcinoma.
Fukuhara M; Agnarsdóttir M; Edqvist PH; Coter A; Ponten F
Arch Dermatol Res; 2016 Aug; 308(6):449-54. PubMed ID: 27262585
[TBL] [Abstract][Full Text] [Related]
37. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
[TBL] [Abstract][Full Text] [Related]
38. Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-b as Involved in the Pathogenesis of Osteosarcoma.
Yang R; Piperdi S; Zhang Y; Zhu Z; Neophytou N; Hoang BH; Mason G; Geller D; Dorfman H; Meyers PA; Healey JH; Phinney DG; Gorlick R
Clin Orthop Relat Res; 2016 Jan; 474(1):178-89. PubMed ID: 26463566
[TBL] [Abstract][Full Text] [Related]
39. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic.
Perez Montiel D; Arispe Angulo K; Cantú-de León D; Bornstein Quevedo L; Chanona Vilchis J; Herrera Montalvo L
Ann Diagn Pathol; 2015 Aug; 19(4):249-52. PubMed ID: 26059401
[TBL] [Abstract][Full Text] [Related]
40. SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas.
Zhang YJ; Chen JW; He XS; Zhang HZ; Ling YH; Wen JH; Deng WH; Li P; Yun JP; Xie D; Cai MY
EBioMedicine; 2018 Feb; 28():62-69. PubMed ID: 29396302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
